The objectives of this study were to investigate the bactericidal activity in serum of cefotaxime alone or in combination with tobramycin against clinical strains and to determine the influence of tobramycin on the pharmacokinetics of cefotaxime. The The bactericidal activity test in serum has been recommended to monitor antimicrobial therapy in patients with serious infections. It is generally agreed upon that a bactericidal activity in serum of >1:8 correlates with the clinical effectiveness of antibiotics (3, 5a, 11), but in a recent review Wolfson and Swartz (12) have concluded that convincing proof of the utility of the bactericidal activity test in serum in the management of infective endocarditis is lacking. Lagast and co-workers studied the bactericidal activity in serum of cefotaxime alone and in association with tobramycin against clinical strains of Pseudomonas aeruginosa and Staphylococcus aureus (4). They observed increased activity of cefotaxime against both strains when used in combination with tobramycin. In this study we extend the investigation of the bactericidal activity in serum of cefotaxime alone or in combination with tobramycin to clinical isolates of Klebsiella oxytoca, Enterobacter aerogenes, Serratia marcescens, Pseudomonas cepacia, and Listeria monocytogenes.
The bactericidal activity test in serum has been recommended to monitor antimicrobial therapy in patients with serious infections. It is generally agreed upon that a bactericidal activity in serum of >1:8 correlates with the clinical effectiveness of antibiotics (3, 5a, 11) , but in a recent review Wolfson and Swartz (12) have concluded that convincing proof of the utility of the bactericidal activity test in serum in the management of infective endocarditis is lacking. Lagast and co-workers studied the bactericidal activity in serum of cefotaxime alone and in association with tobramycin against clinical strains of Pseudomonas aeruginosa and Staphylococcus aureus (4) . They observed increased activity of cefotaxime against both strains when used in combination with tobramycin. In this study we extend the investigation of the bactericidal activity in serum of cefotaxime alone or in combination with tobramycin to clinical isolates of Klebsiella oxytoca, Enterobacter aerogenes, Serratia marcescens, Pseudomonas cepacia, and Listeria monocytogenes.
(This paper was presented at the 14th International Congress of Chemotherapy, Kyoto, Japan, in June 1985.)
Twelve healthy subjects (six females, six males) between the ages of 20 and 24 years (mean, 21.7 years) gave written informed consent to participate in the study. The protocol was approved by the Centre Hospitalier de l'Universite Laval Human Research Review and PharmacologyTherapeutic Committees. The mean weight of the subjects was 64.4 kg (range, 57.0 to 84.5 kg). Based on creatinine and blood urea nitrogen values in serum, these young volunteers had normal renal function. The subjects received 1 g of cefotaxime and, 1 week later, 1 g of cefotaxime with 80 mg of tobramycin. Both antibiotics were diluted in 50 ml of 0.9% sodium chloride and given intravenously over 5 min. When both drugs were given simultaneously, they were never mixed in vitro but were administered at separate venipuncture sites. Tobramycin inactivation by cefotaxime is minimal, even in vitro (2) .
Blood samples were drawn from a catheter (contralateral to the one used for cefotaxime infusion) by the following * Corresponding author. sequence: before drug was administered and at 10, 30, 45, and 60 min and 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 24 h after antibiotic administration. Urine was collected on both study days immediately before injection(s) and at intervals between 0 and 2, 2 and 4, 4 and 8, and 8 and 24 h after antibiotic(s) administration. Each urine sample was stored at -20°C until it was assayed.
Serum and urine samples were analyzed in triplicate for cefotaxime by the high-pressure liquid chromatographic procedure described previously (5); however, the following modifications were made. The serum (0.5 ml) sample preparation involved protein precipitation with 0.25 ml of trichloroacetic acid (10% [wtlvol]) followed by extraction with 2.0 ml of a methyl chloride-isopropanol mixture (90:10). We obtained an absolute recovery of 108%. Under these conditions, the retention for cefotaxime and desacetylcefotaxime was 8.5 and 3.5 min, respectively. The sensitivity limit of the assay was 0.75 ,ug/ml of serum. The coefficient of variation from day to day was less than 5.0%. Linear regression analysis of the standard calibration lines yielded a correlation greater than 0.995, indicating excellent linearity of the assay between 1 and 100 p.g/ml.
Individual plasma concentrations were fitted to the equation given below by nonlinear least-squares analysis (8); initial estimates were determined by a residual method (6). C = Ae-" + Be-', where C represents the concentration of drug in serum, A and B represent the coefficients of the biexponential equation, and a and ,B are the hybrid disposition rate constants. In the analysis, the short infusion time of cefotaxime (5 min) was considered analogous to a bolus injection. The area under the serum concentration-time curve from time zero to infinity (AUC) was calculated by conventional linear trapezoidal and extrapolation methods. MICs and MBCs of cefotaxime and tobramycin against 18 microorganisms were determined by a microtiter dilution assay with Mueller-Hinton broth as the growth medium and diluent. The bactericidal activity of serum samples was determined by a microtiter dilution method using equal quantities of pooled human serum and Mueller-Hinton broth as diluent. The inoculum was 105 bacteria per ml. The bactericidal activity in serum was determined as the last dilution which allowed no growth after each nonturbid well was subcultured onto agar plates (99.9% killing) (7) . Figure 1 shows the mean cefotaxime concentrations in serum in the 12 study subjects after a single intravenous dose. Levels of drug in serum were similar whether the drug was administered alone or in combination with tobramycin. Mean cefotaxime concentrations at 0.5 h were 42.1 ± 9.7 ,ug/ml alone and 30.8 ± 7.4 jxg/ml in combination with tobramycin. At 6 h, these levels were 1.8 ± 0.8 and 1.9 ± 1.0 ,ug/ml, respectively. In contrast with results of the study by Lagast et al. (4) and our own study of netilmicin-ceftazidime combination (5a), tobramycin administration diminished urinary recovery of cefotaxime by 36% and, consequently, the CLR from 183.7 ± 51.7 ml/min to 130.2 ± 40.5 ml/min (P < 0.05). Aronoff and co-workers (1) have also demonstrated that the administration of tobramycin decreases the CLR of moxalactam. Other cefotaxime pharmacokinetic parameters were not affected by tobramycin administration.
The MIC for 90% of strains tested and the MBC of cefotaxime and tobramycin are given in Table 1 . The activity of cefotaxime against K. oxytoca and E. aerogenes was good. Cefotaxime was only moderately active against P. cepacia, S. marcescens, and L. monocytogenes. The MBCs were much higher than the MICs against L. monocytogenes.
The results of bactericidal activity in serum of cefotaxime alone or in combination with tobramycin at 0.5 and 6 h are presented in Table 2 . The data shown are the median values of the activity of the sera of the 12 volunteers against each microorganism. The percentage of serum with bactericidal activity in serum greater than 1:8 is also presented.
In this experiment, cefotaxime administered alone exhibited good bactericidal activity in serum against most pathogens at 0.5 h but limited bactericidal activity in serum 6 h following the 1-g dose. This limited activity at 6 h was most likely due to the short half-life of cefotaxime. Results of our study also suggest that desacetylcefotaxime has limited activity against most pathogens, with the possible exception of K. oxytoca and L. monocytogenes; cefotaxime bactericidal titers of 1:32 were maintained in a high percentage of the serum samples. These observations were confirmed in recent studies (9, 10) .
Tobramycin enhanced the early bactericidal activity of cefotaxime in serum against E. aerogenes from 1:16 to 1:128 (P < 0.01). At 6 h, the combination was significantly more effective against all strains than was cefotaxime alone. Our data are comparable with those of other investigators who have shown a limited increase in the bactericidal activity of cefotaxime when aminoglycosides have been added (4 
